scholarly journals A Clinical Study of Colorectal Cancer Patients with Other Primary Cancer

2007 ◽  
Vol 40 (9) ◽  
pp. 1557-1564 ◽  
Author(s):  
Manabu Shiozawa ◽  
Kazuhito Tsuchida ◽  
Nobuhiro Sugano ◽  
Souichirou Morinaga ◽  
Makoto Akaike ◽  
...  
Vox Sanguinis ◽  
1992 ◽  
Vol 62 (2) ◽  
pp. 102-107 ◽  
Author(s):  
M. A. W. Hoynck Papendrecht ◽  
W. Hop ◽  
B. L. A. M. Langenhorst ◽  
F. C. Kothe ◽  
R. L. Marquet ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Noriyuki Tagai ◽  
Takanori Goi ◽  
Michiaki Shimada ◽  
Hidetaka Kurebayashi

Abstract Background Prokineticin 1 (PROK1) was reported as an angiogenic factor, which is associated with tumor progression, cell invasion, and metastasis in colorectal cancer. Although the association between PROK1 expression in primary cancer lesion and patient prognosis was reported, it is unclear whether plasma PROK1 concentration may be a predictive factor in colorectal cancer patients. This study investigated the association between PROK1 concentration in plasma and prognosis in colorectal cancer patients. Methods We measured preoperative PROK1 plasma levels using ELISA method, while PROK1 expression in primary cancer lesion was evaluated using immunohistochemistry (IHC). The association between plasma PROK1 levels and cancer-related survival rate (CRS) was evaluated. Additionally, we examined whether simultaneous PROK1 expression in both primary cancer lesions and plasma was correlated with CRS. The cancer-related survival rate was calculated using the Kaplan-Meier method, and survival estimates were compared using the log-rank test. Results We have gathered eligible 130 CRC patients retrospectively. Out of 130 patients, 61 (46.9%) were positive on IHC in primary cancer, and 69 (53.1%) were negative, while 43 (33.1%) had high-value PROK1 in plasma. Out of these 43, 30 (25.4%) also had concomitant higher IHC expression in primary cancer. The plasma PROK1 levels tended to increase with advancing stages. The plasma PROK1-positive group had a lower 5-year CRS than the negative group (63.6% vs. 88.2%; P = 0.006). Additionally, simultaneous PROK1 expression was associated with a more significant decrease of 5-year CRS than both negative groups in all stages (76.2% vs. 92.5%; P = 0.003) and stage III (59.3% vs. 84.5%; P = 0.047). Multivariate analysis showed simultaneous PROK1 expression was independently associated with worse CRS (HR, 1.97; 95% CI 1.20‑3.24, P < 0.01). Conclusion PROK1 expression in preoperative plasma reflects poor prognosis in patients undergoing curative resection for colorectal cancer. The plasma PROK1 level may be a potential predictive marker, especially in stage III colorectal cancer patients.


Vox Sanguinis ◽  
1992 ◽  
Vol 62 (2) ◽  
pp. 102-107 ◽  
Author(s):  
M.A.W. Hoynck van Papendrecht ◽  
W. Hop ◽  
B.L.A.M. Langenhorst ◽  
F.C. Kothe ◽  
R.L. Marquet ◽  
...  

2004 ◽  
Vol 13 (1) ◽  
pp. 53-54 ◽  
Author(s):  
Yves Denizot ◽  
Véronique Truffinet ◽  
Stéphane Bouvier ◽  
Alain Gainant ◽  
Pierre Cubertafond ◽  
...  

This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A2) and one in PAF degradation (i.e. PAF acetylhydrolase activity) were significantly elevated.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3546-3546
Author(s):  
Ben Goodman ◽  
Cynthia S Johnson ◽  
Netsanet Gebregziabher ◽  
Mary A. Maluccio ◽  
Paul R. Helft ◽  
...  

3546 Background: Stereotactic body radiation therapy (SBRT) is a non-invasive, effective technique in the treatment of hepatic oligometastases from solid tumors. We present response and local control rates from our single institution experience. Methods: We treated 79 metastatic liver lesions from 64 different patients using stereotactic body radiation therapy. One colorectal cancer patient was treated three times and four patients were treated twice. Among the 79 metastatic liver lesions treated, 85% had prior chemotherapy. The primary cancer site included: Colorectal 66%, Non-colorectal GI 14%, Breast 6%, Ovarian 5%, NSCLC 3%, and other 6%. The mean GTV size was 37.3 (cc). The mean GTV diameter was 3.1 (cm). The median total dose was 54 (Gy) with the minimum and maximum total dose being 30 and 60 (Gy). Results: The overall local control rate was 94.2%, with estimates at 12, 24, 36, and 48 months being 96.1%, 87.9%, 87.9% and 87.9% following SBRT treatment. When comparing colorectal cancer patients vs all other primary cancer sites, the one year local control rate was 93.4% and 100%. The two and three year local control rates for colorectal cancer vs other primary cancer sites were 84.9% vs 90.9%. Best response was examined as a 4 level response (CR,PR,SD,PD) per the RECIST criteria. Overall, 67% of patients had a response, and less than 3% of patients had progression with SBRT treatment. For colorectal cancer patients, 79% had a response to treatment. Only 21% of colorectal cancer patients did not respond, however, the majority of these patients still had stable disease following treatment. Non-colorectal primary site cancers had a response in 50% of the lesions following SBRT treatment. The remaining 50% of non-colorectal primary cancers were stable following SBRT treatment and none progressed. The median dose for CR, PR, or SD was 54 Gy. The median dose for patients with progressive disease was less than 50 Gy. The observed CTC toxicities were limited with mostly grade 1-2 toxicity and only two grade 4 and one grade 5 toxicity. Conclusions: Stereotactic body radiation therapy is an effective treatment option for patients with hepatic oligometastases with a limited toxicity profile.


Sign in / Sign up

Export Citation Format

Share Document